These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
423 related articles for article (PubMed ID: 24315802)
1. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Schiller B; Bhat P; Sharma A Clin Ther; 2014 Jan; 36(1):70-83. PubMed ID: 24315802 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min. Auerbach M; Strauss W; Auerbach S; Rineer S; Bahrain H Am J Hematol; 2013 Nov; 88(11):944-7. PubMed ID: 23828252 [TBL] [Abstract][Full Text] [Related]
3. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease. Schwenk MH Pharmacotherapy; 2010 Jan; 30(1):70-9. PubMed ID: 20030475 [TBL] [Abstract][Full Text] [Related]
4. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Lu M; Cohen MH; Rieves D; Pazdur R Am J Hematol; 2010 May; 85(5):315-9. PubMed ID: 20201089 [TBL] [Abstract][Full Text] [Related]
5. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial . Macdougall IC; Strauss WE; Dahl NV; Bernard K; Li Z Clin Nephrol; 2019 Apr; 91(4):237-245. PubMed ID: 30802204 [TBL] [Abstract][Full Text] [Related]
6. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078 [TBL] [Abstract][Full Text] [Related]
7. Iron indices and intravenous ferumoxytol: time to steady-state. Kapoian T; O'Mara NB; Carreon M; Gajary A; Rizkala A; Lefavour G; Sherman RA; Walker J Ann Pharmacother; 2012 Oct; 46(10):1308-14. PubMed ID: 22968523 [TBL] [Abstract][Full Text] [Related]
8. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale. Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549 [TBL] [Abstract][Full Text] [Related]
9. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178 [TBL] [Abstract][Full Text] [Related]
10. Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease. Coyne DW Expert Opin Pharmacother; 2009 Oct; 10(15):2563-8. PubMed ID: 19708851 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial. Goldstein SL; Morris D; Warady BA Am J Kidney Dis; 2013 Apr; 61(4):588-97. PubMed ID: 23245582 [TBL] [Abstract][Full Text] [Related]
12. Safety of ferumoxytol in patients with anemia and CKD. Singh A; Patel T; Hertel J; Bernardo M; Kausz A; Brenner L Am J Kidney Dis; 2008 Nov; 52(5):907-15. PubMed ID: 18824288 [TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder. Geisser P; Rumyantsev V Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929 [TBL] [Abstract][Full Text] [Related]
14. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Provenzano R; Schiller B; Rao M; Coyne D; Brenner L; Pereira BJ Clin J Am Soc Nephrol; 2009 Feb; 4(2):386-93. PubMed ID: 19176796 [TBL] [Abstract][Full Text] [Related]
15. Safety of total dose iron dextran infusion in geriatric patients with chronic kidney disease and iron deficiency anemia. Dossabhoy NR; Turley S; Gascoyne R; Tapolyai M; Sulaiman K Ren Fail; 2014 Aug; 36(7):1033-7. PubMed ID: 24845687 [TBL] [Abstract][Full Text] [Related]
16. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products. McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312 [TBL] [Abstract][Full Text] [Related]
17. Use of intravenous iron supplementation in chronic kidney disease: an update. Macdougall IC; Geisser P Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. Bailie GR Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930 [TBL] [Abstract][Full Text] [Related]
19. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534 [TBL] [Abstract][Full Text] [Related]
20. Ferumoxytol infusion in pediatric patients with gastrointestinal disorders: first case series. Hassan N; Cahill J; Rajasekaran S; Kovey K Ann Pharmacother; 2011 Dec; 45(12):e63. PubMed ID: 22116997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]